drugset
drugset / Trial / NCT04899219

A Study to Investigate the Pharmacokinetics of ACT-1014-6470 in Subjects With Severe Renal Impairment Compared to Control Subjects

NCT04899219 ↗

Phase 1 Completed 16 enrolled Idorsia Pharmaceuticals Ltd.
Non-randomizedParallel-groupOpen-labelOther

Summary

An open-label, single-dose study to investigate the pharmacokinetics of ACT-1014-6470 in subjects with severe renal impairment compared to control subjects

Timeline

Start
2021-06-16
Primary completion
2021-11-12
Completion
2021-11-12

Drugs

EvaluationDrugModalityDoseRoute
Subject ACT-1014-6470 Unknown 40 mg Oral

Indications

No indication recorded.